Ming Yu Pharmaceutical Limited

明宇制药有限公司

Biotechnology company developing antibody-drug conjugates, a PD-1/VEGF bispecific antibody, and autoimmune drug candidates. Its pipeline of 11 candidates targets solid tumors including NSCLC and breast cancer, and thyroid eye disease, with programs in clinical and late-stage development.

Filings

The documents are on HKEXnews; we link to the originals.

Matters the filing discloses

From the company’s latest filing; open a kind of matter to see how other companies disclosed it.

• Supplier concentration
• Reliance on platforms, partners or licences
• Outsourced production (OEM / contract manufacturing)
• Losses and path to profitability
• Negative operating cash flow
• Cash burn and runway
• Preferred shares and fair-value liabilities
• Chapter 18A biotech